Integrated Cancer Research Site
Search
Actualité - Publications

Therapeutic vulnerability in a medulloblastoma subgroup

SIRIC team
08/11/2020
Partager
Forget et al present an integrated multi-omic medulloblastoma characterization including DNA methylation, copy number, RNA sequencing, proteomics and phosphoproteomics profiling analysis
Cancer Cell journal logo

Medulloblastoma (MB) is the most common pediatric brain tumor. Despite significant clinical progress over the last few decades, this disease is still aggressive. Identifying new treatments is an important clinical question. 

Based on epigenomic and transcriptomic profiles 4 distinct MB subgroups have been identified. 

To better understand their biology, Forget et al associated a proteomics and phosphoproteomics analysis with existing data. Based on this integrative proteogenomic approach, the team were able to identify new therapeutic targets

 

Our scientific program